JP2020530023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530023A5 JP2020530023A5 JP2020506974A JP2020506974A JP2020530023A5 JP 2020530023 A5 JP2020530023 A5 JP 2020530023A5 JP 2020506974 A JP2020506974 A JP 2020506974A JP 2020506974 A JP2020506974 A JP 2020506974A JP 2020530023 A5 JP2020530023 A5 JP 2020530023A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- salt
- compound according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 33
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 description 4
- 0 *CN1C(C*C2)=C2[n]2c(C3(CC3)C3CC3)nnc2C1O Chemical compound *CN1C(C*C2)=C2[n]2c(C3(CC3)C3CC3)nnc2C1O 0.000 description 3
- VGHIZNBWVGBFNE-UHFFFAOYSA-N O=C1N(CC2CC2)C(CCOC2)=C2[n]2c1nnc2C1(CC1)C1CC1 Chemical compound O=C1N(CC2CC2)C(CCOC2)=C2[n]2c1nnc2C1(CC1)C1CC1 VGHIZNBWVGBFNE-UHFFFAOYSA-N 0.000 description 2
- 101001117044 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Proteins 0.000 description 1
- 101001117099 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B Proteins 0.000 description 1
- 101001117094 Homo sapiens Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C Proteins 0.000 description 1
- 101000988419 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4D Proteins 0.000 description 1
- 101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 description 1
- PQARBZOQLPPPEE-UHFFFAOYSA-N N=C(C1(CC1)C1CC1)N(C(CCOC1)=C1N(CC1C=C1)C1=O)C1=N Chemical compound N=C(C1(CC1)C1CC1)N(C(CCOC1)=C1N(CC1C=C1)C1=O)C1=N PQARBZOQLPPPEE-UHFFFAOYSA-N 0.000 description 1
- CVAGLVRPMWLBHS-UHFFFAOYSA-N N=C(C1(CC1)C1CC1)N(C(CCOC1)=C1N(CC1CC1)C1O)C1=N Chemical compound N=C(C1(CC1)C1CC1)N(C(CCOC1)=C1N(CC1CC1)C1O)C1=N CVAGLVRPMWLBHS-UHFFFAOYSA-N 0.000 description 1
- ODMQEFJBGHFGRK-UHFFFAOYSA-N O=C1N(CC2C=C2)C(COCC2)=C2N2C1=NNC2C1(CC1)C1CC1 Chemical compound O=C1N(CC2C=C2)C(COCC2)=C2N2C1=NNC2C1(CC1)C1CC1 ODMQEFJBGHFGRK-UHFFFAOYSA-N 0.000 description 1
- YRQYBCXPHAPHQB-UHFFFAOYSA-N OC1N(CC2CC2)C(CCOC2)=C2[n]2c(C3(CC3)C3CC3)nnc12 Chemical compound OC1N(CC2CC2)C(CCOC2)=C2[n]2c(C3(CC3)C3CC3)nnc12 YRQYBCXPHAPHQB-UHFFFAOYSA-N 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 102000055551 human PDE1A Human genes 0.000 description 1
- 102000055462 human PDE1B Human genes 0.000 description 1
- 102000055048 human PDE1C Human genes 0.000 description 1
- 102000055047 human PDE3A Human genes 0.000 description 1
- 102000048135 human PDE4D Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543427P | 2017-08-10 | 2017-08-10 | |
| US62/543,427 | 2017-08-10 | ||
| PCT/US2018/045081 WO2019032383A1 (en) | 2017-08-10 | 2018-08-03 | [1,2,4] TRIAZOLO DERIVATIVES AS PDE1 INHIBITORS FOR THE TREATMENT OF DIABETES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530023A JP2020530023A (ja) | 2020-10-15 |
| JP2020530023A5 true JP2020530023A5 (https=) | 2020-11-26 |
| JP6834057B2 JP6834057B2 (ja) | 2021-02-24 |
Family
ID=63364164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506974A Active JP6834057B2 (ja) | 2017-08-10 | 2018-08-03 | 糖尿病の治療のためのｐｄｅ１阻害剤としての［１，２，４］トリアゾロ誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11401274B2 (https=) |
| EP (1) | EP3665174B1 (https=) |
| JP (1) | JP6834057B2 (https=) |
| CN (1) | CN110914273B (https=) |
| AR (1) | AR112346A1 (https=) |
| ES (1) | ES2895969T3 (https=) |
| TW (1) | TW201920188A (https=) |
| WO (1) | WO2019032383A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113072453A (zh) * | 2021-04-08 | 2021-07-06 | 红宝丽集团股份有限公司 | 一种2-氨基环烷醇的制备方法 |
| AU2024341364A1 (en) | 2023-09-14 | 2026-03-26 | Eli Lilly And Company | Pde1 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4354027A (en) * | 1980-05-19 | 1982-10-12 | Usv Pharmaceutical Corporation | Triazoloquinoxalin-4-ones |
| FR2662163A1 (fr) * | 1990-05-16 | 1991-11-22 | Lipha | Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant. |
| CN1285834A (zh) | 1997-11-11 | 2001-02-28 | 小野药品工业株式会社 | 稠合吡嗪化合物 |
| ATE503756T1 (de) * | 2005-09-29 | 2011-04-15 | Glaxo Group Ltd | Pyrazoloä3,4-büpyridinverbindungen und ihre verwendung als pde4-inhibitoren |
| CA2671980C (en) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| WO2008103357A1 (en) | 2007-02-21 | 2008-08-28 | E. I. Du Pont De Nemours And Company | Fungicidal tricyclic 1,2,4-triazoles |
| BR112013005439A2 (pt) * | 2010-09-07 | 2017-09-19 | Astellas Pharma Inc | compostos de quinoxalina |
| MX357320B (es) * | 2012-06-18 | 2018-07-04 | Dart Neuroscience Cayman Ltd | Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida. |
| TWI609870B (zh) * | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
| JOP20170164A1 (ar) | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
-
2018
- 2018-07-27 TW TW107126001A patent/TW201920188A/zh unknown
- 2018-07-27 AR ARP180102122 patent/AR112346A1/es unknown
- 2018-08-03 CN CN201880051513.1A patent/CN110914273B/zh active Active
- 2018-08-03 JP JP2020506974A patent/JP6834057B2/ja active Active
- 2018-08-03 ES ES18759465T patent/ES2895969T3/es active Active
- 2018-08-03 WO PCT/US2018/045081 patent/WO2019032383A1/en not_active Ceased
- 2018-08-03 US US16/628,164 patent/US11401274B2/en active Active
- 2018-08-03 EP EP18759465.0A patent/EP3665174B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133474A5 (https=) | ||
| JP2010525056A5 (https=) | ||
| RU2009117388A (ru) | Моногидрат 4-[4-({[4-хлор-3-(трифторметил)фенил]карбамоил})амино)-3-фторфенокси]-n-метилпиридин-2-карбоксамида | |
| JP2016528301A5 (https=) | ||
| JP2016525122A5 (https=) | ||
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2009542699A5 (https=) | ||
| JP2017526677A5 (https=) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2015523397A5 (https=) | ||
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| JP2017531619A5 (https=) | ||
| JP2015522589A5 (https=) | ||
| JP2020507589A5 (https=) | ||
| JP2015532296A5 (https=) | ||
| JP2019501879A5 (https=) | ||
| JP2016522254A5 (https=) | ||
| RU2015114967A (ru) | Производные ингенола, применяемые для лечения рака | |
| RU2007120710A (ru) | Способ лечения рака и/или лейкоза и применяемая в нем фармацевтическая композиция | |
| JP2020530023A5 (https=) | ||
| JP2014532063A5 (https=) | ||
| RU2018114457A (ru) | Лечение syd985 пациентов с t-dm1 рефрактерным раком | |
| JP2019516726A5 (https=) | ||
| JP2020529413A5 (https=) | ||
| JP2006517195A5 (https=) |